Women’s Brain Health Initiative (WBHI), an organisation that aims to help protect the brain health of women, their caregivers, and their families, is celebrating its fifth annual Women’s Brain Health Day.
On 2 December (Women’s Brain Health Day), WBHI will run in-person and online events with brain health experts to discuss the benefits of creativity and exercise on the brain, as well as to raise money for women’s brain health.
Women’s Brain Health Day is becoming increasingly important because of the disproportionate number of women affected by Alzheimer’s disease.
Approximately 70% of those diagnosed with Alzheimer’s disease are women. Additionally, according to the Global Burden of Disease Study 2019, the number of people diagnosed with dementia is expected to almost triple by 2050.
The World Health Organization (WHO) estimates that 60%-70% of dementia cases could actually be Alzheimer’s disease.
With the number of both dementia and Alzheimer’s diagnoses expected to increase significantly in the coming years, devices to help diagnose and manage Alzheimer’s disease are more important now than ever.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Currently, the Alzheimer’s disease market is valued at $2.7bn and is forecast to grow at a compound annual growth rate of 29%, reaching $16bn by 2030, according to GlobalData forecasts.
The GlobalData Marketed Products database shows 141 marketed devices that use Alzheimer’s disease as an indication.
Regarding those 141 products, almost half (46%) are within the in vitro diagnostics (IVD) therapy area, meaning many of the devices are tests to help diagnose Alzheimer’s disease.
Following IVD, the second most common device type for Alzheimer’s disease in the Marketed Products database falls under healthcare IT (26%).
Healthcare IT devices include many digital health devices and solutions, including apps or software that aid IVD tests by evaluating brain function.
However, some are also used for disease management. For example, the software CST-Therapist Companion (developed by Brain+ApS) is designed to stimulate and improve cognition through psychosocial interaction to create associations with existing memories.
These types of apps and programmes could be useful for the management or even prevention of Alzheimer’s disease, as mental stimulation and social activity are both important factors in the disease’s prevention.
While not every case of Alzheimer’s disease is preventable, some are. In addition to mental stimulation and social activity, some key prevention factors are exercise, diet, healthy sleep patterns, and managing stress levels.